Ablation combined with video-assisted thoracic surgery hybrid technique for multiple primary lung cancer.

Publication date: Jun 20, 2025

Increased public health awareness and expanded low-dose computed tomography (CT) utilization, accelerated by the COVID-19 pandemic, have elevated detection rates of pulmonary ground-glass nodules (GGNs). Patients with multiple primary lung cancer (MPLC) often present with multiple GGNs, posing challenges for precise treatment and prognostic assessment. Current therapies including stereotactic body radiation therapy (SBRT), chemotherapy, and immunotherapy face efficacy and safety limitations. While video-assisted thoracic surgery (VATS) is the primary treatment for high-risk GGNs, the sole reliance on surgery may cause excessive loss of lung function. Image-guided thermal ablation techniques can effectively treat smaller lesions with lung preservation. This review explores molecular mechanisms of ablation, VATS-ablation synergy, and the potential value of this approach in combination with immunotherapy. The clinical application prospects, including advancements in navigation techniques and equipment, are also discussed. Overall, this hybrid surgical strategy represents a promising option for patients with multiple lesions, minimizing lung function loss and the psychological burden.

Open Access PDF

Concepts Keywords
Cancer Cancer
Immunotherapy Medical procedure
Lung Surgery
Synergy
Tomography

Semantics

Type Source Name
disease MESH lung cancer
disease MESH COVID-19 pandemic
disease MESH Cancer
drug DRUGBANK Coenzyme M
disease MESH tics
disease MESH metastasis
disease MESH death
disease MESH hyperthermia
disease MESH hypothermia
drug DRUGBANK Gold
disease MESH hyperplasia
disease MESH adenocarcinoma
disease MESH lung adenocarcinoma
disease MESH carcinoma
disease MESH residual tumor
disease MESH complications
disease IDO immune response
disease MESH necrosis
pathway REACTOME Apoptosis
drug DRUGBANK Tretamine
drug DRUGBANK Trestolone
disease MESH abnormalities
disease MESH mitochondrial dysfunction
disease MESH causes
disease MESH shock
drug DRUGBANK Hyaluronic acid
disease MESH immune tolerance
disease IDO cell
disease MESH inflammation
drug DRUGBANK Water
pathway REACTOME Autophagy
disease MESH depression
disease IDO process
pathway REACTOME Metabolism
disease IDO susceptibility
drug DRUGBANK Nitrogen
drug DRUGBANK Flunarizine
disease IDO history
disease MESH contraindications
drug DRUGBANK Prothrombin

Original Article

(Visited 2 times, 1 visits today)